Literature DB >> 17303312

Functions, dysfunctions and possible therapeutic relevance of adenosine A2A receptors in Huntington's disease.

Patrizia Popoli1, David Blum, Alberto Martire, Catherine Ledent, Stefania Ceruti, Maria P Abbracchio.   

Abstract

The aim of this review is to summarize and critically discuss the complex role played by adenosine A(2A) receptors (A(2A)Rs) in Huntington's disease (HD). Since A(2A)Rs are mainly localized on the neurons, which degenerate early in HD, and given their ability to stimulate glutamate outflow and inflammatory gliosis, it was hypothesized that they could be involved in the pathogenesis of HD, and that A(2A)R antagonists could be neuroprotective. This was further sustained by the demonstration that A(2A)Rs and underlying signaling systems undergo profound changes in cellular and animal models of HD. More recently, however, the equation A(2A) receptor blockade=neuroprotection has appeared too simplistic. First, it is now definitely clear that, besides mediating 'bad' responses (for example, stimulation of glutamate outflow and excessive glial activation), A(2A)Rs also promote 'good' responses (such as trophic and antinflammatory effects). This implies that A(2A)R blockade results either in pro-toxic or neuroprotective effects according to the mechanisms involved in a given experimental model. Second, since HD is a chronically progressive disease, the multiple mechanisms involving A(2A)Rs may play different relative roles along the degenerative process. Such different mechanisms can be influenced by A(2A)R activation or blockade in different ways, even leading to opposite outcomes depending on the time of agonist/antagonist administration. The number, and the complexity, of the possible scenarios is further increased by the influence of mutant Huntingtin on both the expression and functions of A(2A)Rs, and by the strikingly different effects mediated by A(2A)Rs expressed by different cell populations within the brain.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17303312     DOI: 10.1016/j.pneurobio.2006.12.005

Source DB:  PubMed          Journal:  Prog Neurobiol        ISSN: 0301-0082            Impact factor:   11.685


  24 in total

1.  Caffeine exposure ameliorates acute ischemic cell death in avian developing retina.

Authors:  D Pereira-Figueiredo; R Brito; D S M Araújo; A A Nascimento; E S B Lyra; A M S S Cheibub; A D Pereira Netto; A L M Ventura; R Paes-de-Carvalho; K C Calaza
Journal:  Purinergic Signal       Date:  2020-02-20       Impact factor: 3.765

2.  A2A adenosine receptor deletion is protective in a mouse model of Tauopathy.

Authors:  C Laurent; S Burnouf; B Ferry; V L Batalha; J E Coelho; Y Baqi; E Malik; E Mariciniak; S Parrot; A Van der Jeugd; E Faivre; V Flaten; C Ledent; R D'Hooge; N Sergeant; M Hamdane; S Humez; C E Müller; L V Lopes; L Buée; D Blum
Journal:  Mol Psychiatry       Date:  2014-12-02       Impact factor: 15.992

Review 3.  Huntington's disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease.

Authors:  Michelle E Ehrlich
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

4.  Functional changes in postsynaptic adenosine A(2A) receptors during early stages of a rat model of Huntington disease.

Authors:  Marco Orrú; Janaina Menezes Zanoveli; César Quiroz; Huu Phuc Nguyen; Xavier Guitart; Sergi Ferré
Journal:  Exp Neurol       Date:  2011-08-16       Impact factor: 5.330

5.  Identification of anti-inflammatory targets for Huntington's disease using a brain slice-based screening assay.

Authors:  Peter H Reinhart; Linda S Kaltenbach; Christian Essrich; Denise E Dunn; Joshua A Eudailey; C Todd DeMarco; Gregory J Turmel; Jennifer C Whaley; Andrew Wood; Seongeun Cho; Donald C Lo
Journal:  Neurobiol Dis       Date:  2011-03-31       Impact factor: 5.996

6.  GDNF control of the glutamatergic cortico-striatal pathway requires tonic activation of adenosine A receptors.

Authors:  Catarina A R V Gomes; Patrícia F Simões; Paula M Canas; César Quiroz; Ana M Sebastião; Sergi Ferré; Rodrigo A Cunha; Joaquim A Ribeiro
Journal:  J Neurochem       Date:  2009-01-29       Impact factor: 5.372

Review 7.  Adenosine receptors as drug targets--what are the challenges?

Authors:  Jiang-Fan Chen; Holger K Eltzschig; Bertil B Fredholm
Journal:  Nat Rev Drug Discov       Date:  2013-04       Impact factor: 84.694

Review 8.  Caffeine and anaerobic performance: ergogenic value and mechanisms of action.

Authors:  J K Davis; J Matt Green
Journal:  Sports Med       Date:  2009       Impact factor: 11.136

Review 9.  Adenosine as a neuromodulator in neurological diseases.

Authors:  Detlev Boison
Journal:  Curr Opin Pharmacol       Date:  2007-10-17       Impact factor: 5.547

10.  Adenosine A(2A) receptor mediates microglial process retraction.

Authors:  Anna G Orr; Adam L Orr; Xiao-Jiang Li; Robert E Gross; Stephen F Traynelis
Journal:  Nat Neurosci       Date:  2009-06-14       Impact factor: 24.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.